Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (AML) not eligible for intensive chemotherapy (IC)

Bibliographische Detailangaben
Hauptverfasser:	DiNardo, CD, Dohner, H, Zeidan, AM, Schuh, AC, Vyas, P, Stein, EM, Wei, AH, de Botton, S, Chen, C, Lord-Bessen, J, Martin-Regueira, P, Lersch, F, Gong, J, Guo, S, Shi, L, Montesinos, P
Format:	Conference item
Sprache:	English
Veröffentlicht:	American Society of Hematology 2021

Ähnliche Einträge